Photophysical and Biological Studies with Organometallic Ruthenium Complexes of Selenodiazole Ligands

被引：0
作者：
Raja Mitra
V. S. Sridevi
Kumaravel Somasundaram
Ashoka G. Samuelson
机构：
[1] Indian Institute of Science,Department of Inorganic and Physical Chemistry
[2] Indian Institute of Science,Department of Molecular and Cellular Biology
[3] Universität Duisburg-Essen,Institut für Organische Chemie
来源：
Proceedings of the National Academy of Sciences, India Section A: Physical Sciences | 2016年 / 86卷
关键词：
Piazselenol; Half-sandwich; Ligand dissociation; Imaging agents; Anticancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Substituted selenodiazoles (piazselenols) were used as ligands to synthesize organometallic ruthenium(II) piano-stool complexes using the precursors ([η6-cymene)RuX2 (where x = Cl, Br and I). Analytical data suggested that two (η6-cymene)Ru motifs were present per ligand in the solid state. However, 1H and 77Se NMR in DMSO solution confirmed the dissociation of the selenodiazole ligand from the ruthenium center. Interestingly, selenodiazole with naphthalene substitutes possess excellent photophysical properties. It showed strong red fluorescence (576 nm) when excited at visible region (488 nm) and was found suitable for use as an imaging agent in HCT 116 cells. Among all ligands examined, only the nitro substituted selenodiazole showed potent anticancer activity against the A2780 cell line.
引用
收藏
页码：511 / 520
页数：9
相关论文
共 275 条
[1]  
Rosenberg B(1965)Inhibition of cell division in Nature 205 698-699
[2]  
Van Camp L(2007) by electrolysis products from a platinum electrode Coord Chem Rev 251 1633-1648
[3]  
Krigas T(2013)Using coordination chemistry to design new medicines Chem Commun 49 5106-5131
[4]  
Ronconi L(2015)Exploration of the medical periodic table: towards new targets Coord Chem Rev 284 329-350
[5]  
Sadler PJ(2003)Noble metals in medicine: latest advances Clin Cancer Res 9 1898-1905
[6]  
Barry NPE(2004)Dual action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen Clin Cancer Res 10 3717-3727
[7]  
Sadler PJ(2008)A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent Chem Biodivers 5 2140-2155
[8]  
Medici S(2012)KP1019, a new redox-active anticancer agent—preclinical development and results of a clinical phase I study in tumor patients BMC Pharmacol Toxicol 13 A82-3375
[9]  
Peana M(2013)NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer Eur J Cancer 49 3366-3621
[10]  
Nurchi VM(2001)The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo J Med Chem 44 3616-1657
12345678910